





# Production of omics data: Proteomics





## What is behind these data?

					-	-	-			1							-			
1													Normalized	abundance					Destinat	
2		D				- 14-1						D	Sain	1045007 50	0.05007.55	1015007 57	1045007 50	1045007 544	Patient	4045007 5
3 AC	cession	Peptide col Uni	ique per C	onfidence	Anova (p)	q Value	Max fold ch	Power	Highest me	Lowest mea	Mass	Description	1845007-F1	1845007-F3	1845007-F5	1845007-F7	1845007-F9	1845007-F11	1845007-F2	1845007-F4
4 P4	0197	12	12	545.23	2.48E-07	4.74E-05	32.042418	1	Patient	Sain	60.921	Platelet glycoprotein V US	1447.8857	898.47877	2114.249	3517.982	2506.9091	1186./152	331/8.605	/3995./8
5 P0	2776	2	2	134.77	2.63E-07	4.74E-05	78.817355	1	Patient	Sain	10.838	Platelet factor 4 OS=Homo	3812.4369	3755.8358	1044.3911	2939.4867	3862.0883	1110.5549	333829.66	68071.51
6 Q1	13201	6	6	221.4	5.33E-07	6.40E-05	72.663027	1	Patient	Sain	138.023	Multimerin-1 OS=Homo sa	160.48528	939.93933	155.7663	732.57482	572.39757	196.60688	75519.303	23299.12
7 P0	4114	336	334	28302.18	7.99E-06	0.0006593	2.1384481	1	Patient	Sain	515.283	Apolipoprotein B-100 OS=	14117253	10601958	8472023.6	9982572.2	10056625	11898407	24415094	1744463:
8 P0	7996	42	42	2678.71	9.16E-06	0.0006593	143.08362	1	Patient	Sain	129.3	Thrombospondin-1 OS=Hc	11604.367	10346.75	4059.3393	5652.5533	2121.1343	2367.1543	2303007.2	83175.08
9 Q1	15485	7	7	289.57	1.42E-05	0.0007087	24.427918	0.9999997	Patient	Sain	33.98	Ficolin-2 OS=Homo sapier	8778.176	6132.5206	10104.107	8194.6312	8690.2929	1737.9715	185819.2	105024.9
10 P1	.0720	3	3	208.63	1.49E-05	0.0007087	36.552808	0.9999997	Patient	Sain	11.545	Platelet factor 4 variant O	32881.787	11758.269	1451.6395	5448.2604	4187.5362	4196.5766	546497.96	239272.0
11 Q1	12884	2	2	70.47	1.58E-05	0.0007087	Infinity	0.9999996	Patient	Sain	87.657	Prolyl endopeptidase FAP	0	0	0	0	0	0	961.55592	106.477
12 Q1	15061	1	1	3.67	3.71E-05	0.0014832	23.811179	0.9999905	Sain	Patient	74.843	WD repeat-containing pro	567513.12	751475.75	852125.74	1189728.8	625225.18	78135.037	46681.126	36585.06
13 PO	4075	8	8	371.85	4.58E-05	0.0016488	4.2937733	0.9999814	Patient	Sain	39.395	Fructose-bisphosphate al	33219.801	26234.171	28730.699	26696.908	33816.665	32024.353	128602.25	168571.
14 PO	9486	10	9	463.23	6.25E-05	0.0020451	6.1746973	0.999953	Patient	Sain	34.61	SPARC OS=Homo sapiens (	9522.5101	37758.131	36721.019	20388.641	15117.423	28228.93	299004.24	97804.24:
15 P1	.0124	1	1	70.16	7.11E-05	0.002134	272.44302	0.9999321	Patient	Sain	17.641	Serglycin OS=Homo sapier	67.740323	0	958.26875	53.15204	160.31231	238.84011	105180.09	42246.24
16 PO	2775	6	6	388.98	8.21E-05	0.0022557	28.012451	0.9998996	Patient	Sain	13.885	Platelet basic protein OS=	61607.9	109352.83	105910.89	67216.894	60865.635	22752.188	3524260.5	1692399.
17 Q9	9H1K0	2	2	12.94	8.77E-05	0.0022557	1.8919044	0.9998799	Patient	Sain	88.815	Rabenosyn-5 OS=Homo sa	871721.79	1194024.5	1103071.3	1121288.3	1020557.4	1361492.9	1506333.1	1757466.9
18 P3	5542	4	4	338.41	0.0001236	0.0029659	16.656374	0.9997122	Patient	Sain	14.737	Serum amyloid A-4 protein	192222.76	102064.74	9416.0169	8023.3014	46690.651	107524.48	1543185.2	1741696.
19 P8	0188	6	6	223.58	0.0001847	0.0041561	9.1194461	0.9992657	Patient	Sain	22.574	Neutrophil gelatinase-as	2265.4484	1473.9176	6203.72	3676.0015	7827.3304	4603.3796	66633.817	26485.80
20 PO	2144	4	4	209.23	0.0002392	0.0050651	6.5032553	0.9987201	Patient	Sain	17.173	Myoglobin OS=Homo sapi	2754.3333	2223.1201	1035.6898	1813.5104	1462.164	5472.3528	17977.389	20813.25
21 PO	5067	5	5	179.76	0.000297	0.0059397	18.947351	0.9980148	Patient	Sain	86.888	Amyloid beta A4 protein C	408.20926	53.510036	338.118	494.28658	258.47482	516.31147	8561.0101	2161.775
22 Q9	ONPH3	7	7	223.36	0.0003417	0.0064734	2.9534965	0.9973949	Patient	Sain	65.377	Interleukin-1 receptor acc	19269.326	23550.392	17918.705	19071.463	29165.24	20448.453	74326.28	82743.30
23 P2	2352	7	7	322.73	0.0005632	0.0101356	2.3655577	0.9936247	Patient	Sain	25.537	Glutathione peroxidase 3	356078.09	500176.63	411199.92	354267.54	608490.2	620677.21	1139291.1	1214566.0
24 A0	A075B610	1	1	30.88	0.0005981	0.0102519	15.884721	0.9929515	Sain	Patient	12.806	Immunoglobulin lambda	14017.761	25223.891	6493.2483	70640.84	15600.774	36585.067	4641.3232	1487.298
25 PO	5155	33	33	2513.9	0.0007389	0.0120898	5.4023431	0.9900925	Patient	Sain	55.119	Plasma protease C1 inhib	741421.19	592478.75	377555.54	465885.04	2331779.9	7791080.5	11109177	1051176
26 A0	AOC4DH2	2	2	100.38	0.0013344	0.0208833	3.8865369	0.9766266	Sain	Patient	12.999	Immunoglobulin heavy va	50500.146	64330.439	38938.111	121804.39	27881.723	32180.678	24057.435	17302.86
27 P1	4780	6	6	207.75	0.0014988	0.0221418	62.066206	0.972746	Patient	Sain	78.408	Matrix metalloproteinase	794.97907	136.39171	262.24899	313.84328	0	555.64619	58928.664	9636.858
28 P0	2649	27	27	1941.9	0.0015378	0.0221418	2.4710215	0.971824	Patient	Sain	36,132	Apolipoprotein E OS=Hom	2552396.1	1536331.8	853676.88	1079240.3	1188651.7	1327575.2	2857655.7	2177433.
29 03	BC1V8	1	1	14.2	0.0019728	0.0268284	5.551993	0.9615339	Patient	Sain	25,917	Brain-specific homeobox	119,76184	56,50442	16.821931	8.5075688	3888.8817	85,190432	6077.0842	3199.583
30 P0	2652	11	11	995.34	0.0020124	0.0268284	2,4014067	0.9606031	Patient	Sain	11.168	Apolipoprotein A-II OS=Ho	34056410	26771849	14632439	15663194	42268641	26890744	89512485	4323663
31 P0	8571	12	12	937.27	0.0025308	0.0320335	1,6971067	0.9485492	Sain	Patient	40.051	Monocyte differentiation	797874.17	434080.26	499432.28	477652.53	733837.28	418725.29	352767.33	318079.3
32 P2	6927	31	31	1222 76	0.0025808	0.0320335	3 3123536	0 9474046	Patient	Sain	80 268	Hepatocyte growth facto								380083.0
33 P0	2655	6	6	819 16	0.0030504	0.0361789	4 7206762	0 9368237	Patient	Sain	11 277	Apolipoprotein C-II OS=								1376230
34 P0	2671	8	8	369.69	0.0031158	0.0361789	191 8384	0.9353762	Patient	Sain	94 914	Fibringen alpha chain								107899
35 00	2763	17	17	1378 36	0.0036234	0.0407586	2 8533872	0.924364	Sain	Patient	23 497	Alpha-1-acid glycoprote			-					2274357
36 01	4831	1	1	23.81	0.0038979	0.0425178	2 9788784	0.9185746	Sain	Patient	102 185	Metabotronic glutamate					100			31759 88
37 P0	2647	32	32	2367.65	0.0040205	0.0425648	2 2688435	0.9160271	Patient	Sain	30 759	Apolinoprotein A-LOS=F								27802701
38 00	1876	21	21	1557.26	0.0044316	0.0455765	3 5420267	0.9100271	Sain	Patient	37 631	Ig alpha-1 chain Cregio				1	12			5212718
39 09		8	8	200	0.005259	0.0525841	1 7900311	0.9015210	Sain	Patient	55 016	Multiple inosital polypl					~			30358 52
40 01	16052	2	2	01 53	0.005233	0.0523841	6 1426712	0.0913213	Sain	Patient	04 550	Mombrano osimany ami					and the second se			104 7405
40 0	10033	2	2	210.55	0.0034293	0.0526194	0.1450/15	0.0003207	Sain	Patient	04.300	Nemorane primary anni Delumeris immuneglebi					0			194.7495.
41 PU	7160	20	0	219.00	0.000944	0.0050448	9.1555004	0.0014401	Datient	Patient	03.232	Polymenc immunoglobi			-					2465.550.
42 12	0174	20	2/	2004.1	0.00/1004	0.0050448	2.0100777	0.05200004	Patient	Sain	39.700	Serum paraoxonase/ary			6					4675 5004
45 Pb	01/4	1	1	28.75	0.0074774	0.0050448	2.9100///	0.0506051	Patient	Salli	30.772	mosephosphate isome					1			40/0.089
44 P0	0/36	41	39	3067.37	0.00/4//1	0.0656448	1.4866/01	0.8526056	Sain	Patient	80.067	complement CIr subcon					5			2638367.
45 P0	98/1	3/	37	2588.95	0.0085558	0.0726349	1.93603	0.835606	sain	Patient	/6.635	complement CIs subcor				-				2302/98.1
46 A0	AUB4J1V0	3	3	104.52	0.0086/69	0.0726349	2.7965659	0.833766	Sain	Patient	12.917	immunoglobulin heavy va	92353.003	20397.701	40/90.52	8/239.028	43133.80/	81018.911	38434.812	1/11/.34
47 P0	1619	4	4	262.21	0.0095577	0.0781901	2.30903	0.8207663	Sain	Patient	12.549	immunoglobulin kappa va	409287.43	332471.99	228180.64	675002.86	220569.52	187876.28	139130.56	148976.3
48 Q0	08380	21	21	1485.84	0.0115602	0.0900161	2.528023	0.7934679	Sain	Patient	65.289	Galectin-3-binding protei	938408.99	614190.09	1091308.6	2622296.8	1676638.8	2590031.7	640186.94	906404.5
49 P0	6/32	9	9	314.24	0.0117011	0.0900161	5.8938011	0.7916528	Patient	Sain	43.074	Creatine kinase M-type O	7288.867	9691.0748	1004.0051	6516.3248	4494.7392	6004.4549	19154.379	89665.94

## CONCEPT



## **GENOMICS vs PROTEOMICS**

#### Genome (DNA)

#### Proteome (proteins)

- Static (no change with time)
- Can be amplified (PCR)
- Little sample complexity
- (4 base pairs, very similar, same order of concentration)
- Good solubility

- Dynamic
- (highly variable with time; many proteomes for one genome)
- Cannot be amplified
- High sample complexity (wide variety of physical and chemical properties; concentrations can differ by 9 orders of magnitude)
- Various solubility; some proteins are insoluble in water



<u>Alanine</u>	A, Ala	71.079
<u>Arginine</u>	R, Arg	156.188
<u>Asparagine</u>	N, Asn	114.104
Aspartic acid	D, Asp	115.089
<u>Cysteine</u>	C, Cys	103.145
<u>Glutamine</u>	Q, Gln	128.131
<u>Glutamic acid</u>	E, Glu	129.116
Glycine	G, Gly	57.052
<u>Histidine</u>	H, His	137.141
<u>Isoleucine</u>	I, lle	113.160
<u>Leucine</u>	L, Leu	113.160
<u>Lysine</u>	K, Lys	128.17
<u>Methionine</u>	M, Met	131.199
Phenylalanine	F, Phe	147.177
Proline	P, Pro	97.117
<u>Serine</u>	S, Ser	87.078
<b>Threonine</b>	T, Thr	101.105
<u>Tryptophan</u>	W, Trp	186.213
<b>Tyrosine</b>	Y, Tyr	163.176
Valine	V, Val	99.133

# **Proteomics?**

- Proteomics is the large-scale study of proteomes, it means all proteins from a cell, an organelle, a tissue, an organ or from an organism at a one point, under specific conditions.
- Proteomics is at the crossroads of biochemistry, analytical chemistry and bioinformatics.
- ⇒Proteins can be modified by different biological or chemical processes; The different variants of proteins are called now: Proteoforms

Nat Methods. 2013 Mar;10(3):186-7. doi: 10.1038/nmeth.2369. Proteoform: a single term describing protein complexity. Smith LM, Kelleher NL; Consortium for Top Down Proteomics

# **PROTEOMICS GOALS**

- Identification of all proteins in a proteome
- Search for new, hypothetical or predicted proteins
- Analysis of differential expression between 2,3,... different conditions (protein up- or downregulation)
- Identification of post-translational modifications
- Characterization of proteins by function, pathway, cellular location, etc.
- Study of protein-protein interactions

# **Proteomics techniques**

#### Prefractionation Immunoaffinity, RP-LC, FFE, liquid-phase IEF, 1D-SDS-PAGE, SCX, etc. Gel-based proteomics **MS-based** proteomics Antibody-based proteomics 2D-DIGE **Trypsin digestion High-throughput** antibody-based assays Peptide labeling or not ELISA Luminex<sup>™</sup>system Quantification Shotgun proteomics Antibodymicroarray Mutidimensional LC fractionation + MS/MS Software image analysis + statistics MS-based protein Identification and quantification Quantification identification SILAC, iTRAQ, spectral count, MRM, SRM Bioinformatics + statistics Bioinformatics + statistics Pathway analysis **Multivariate statistics** No. of Lot, of Studio Pathway, Ingenuity String, KEGG, etc. PCA, PLS-DA, HC, etc.

Discriminant set of proteins



Statistics	
Organs/cell types	30
Genes identified	17,294
Proteins identified	30,057
Peptide sequences	293,700
N-terminal peptides	4,297
Splice junctional peptides	66,947
Samples	85
Adult tissues	17
Fetal tissues	7
Cell types	6

#### Welcome to ProteomicsDB!

ProteomicsDB is a joint effort of the Technische Universität München ( human proteome and its use across the scientific community.



Browse proteins Explore the human proteome protein by protein.

#### Status

Human Proteome	
Coverage:	80%
Proteins:	15721 of 19629
Isoforms:	11353 of 86771
Unique Peptides (Isoform):	113944
Unique Peptides (Gene):	455289
Spectra:	43237800
Repository	
Registered Users:	533
Projects:	75
Experiments:	397
Files:	19459
Data Volume:	7.84 TB

## Problem of proteome complexity



## Evolution of proteomics performances



## Inherent dilemma linked to proteomics



http://www.piercenet.com/method/quantitative-proteomics

## Dynamic range in human plasma



plasma proteins

#### **Proteomics and proteome coverage**



Dynamic range of proteomes

## **Key questions in proteomics**

- What is the protein content of my biological sample?
  => problem of identification
- What is the abundance of my protein of interest?
  => quantification
- Relative question: What are the protein abundance variations of the proteomes studied?
- What are the partners of my protein of interest?
- Are there any signature proteins related to a particular biological process?

=> biomarkers identifications and quantifications



## Instrumentations



## **Proteomics workflows**



## BOTTOM-UP PROTEOMICS: PRO'S AND CON'S

#### **Advantages**

- Less sophisticated instrumentation and expertise
- High throughput
- More info about proteins with "extreme" phys.-chem. properties (hydrophobic, Hi/Low MW, acidic/basic)

#### **Disadvantages**

- Confidence in protein ID strongly depends on restriction criteria (subjective; potential bias)
- Since protein ID is often done by 1-2 peptides, PTM and isoform information is often lost

# **Cleavage rules of proteases**

Enzyme or Reagent	Cleaves where?	Exceptions						
Trypsin	C-terminal side of K or R	if P is C-term to K or R						
Trypsin	(C-term to K/R, even before P)	C-terminal side of K or R						
Trypsin (higher specificity)	C-terminal side of K or R	if P is C-term to K or R;						
		after K in CKY, DKD, CKH, CKD, KKR;						
		after R in RRH, RRR, CRK, DRD, RRF, KRR						
Lys C	C-terminal side of K							
CNBr	C-terminal side of M							
Arg C	C-terminal side of R	if P is C-term to R						
Asp N	N-terminal side of D							
Asp N + N-terminal Glu	N-terminal side of D or E							
Glu C (bicarbonate)	C-terminal side of E	if P is C-term to E, or if E is C-term to E						
Glu C (phosphate)	C-terminal side of D or E	if P is C-term to D or E, or if E is C-term to D or E						
Chymotrypsin	(C-term to F/Y/W/M/L, not before P, not	after Y if P is C-term to Y)						
	C-terminal side of F, L, M, W, Y	if P is C-term to F, L, M, W, Y, if P is N-term to Y						
Chymotrypsin (C-term to I	F/Y/W/, not before P, not after Y if P is C-t	erm to Y)						
	C-terminal side of F, Y, W	if P is C-term to F, Y, W, if P is N-term to Y						
Trypsin/Chymotrypsin (C-term to K/R/F/Y/W, not before P, not after Y if P is C-term to Y)								
	C-terminal side of K, R, F, Y, W	if P is C-term to K, R, F, Y, W, if P is N-term to Y						
Pepsin (pH 1.3)	C-terminal side of F, L							
Pepsin (pH > 2)	C-terminal side of F, L, W, Y, A, E, Q							
Proteinase K	C-terminal side of A, C, G, M, F, S, Y, W							

#### PEPTIDE LENGTH AND NUMBER OF PEPTIDES GENERATED DEPENDING ON ENZYME USED FOR DIGESTION

Other enzymes with more or less specific cleavage:



Advantages of a new proteomic approach that uses accurate mass measurements, LC retention time, isoelectric point and dual enzymatic digestion. Petritis K. et. al., Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352; ASMS'2007 poster presentation http://www.chem.agilent.com/Library/posters/Public/Petritis\_ASMS\_2007.pdf

## What is MS?



## MS and MS/MS



#### MALDI ionization (Matrix Assisted Laser Desorption Ionization)



- L'échantillon (A) est mélangé avec un excès de matrice (M) et séché sur la plaque MALDI
- 2. Le flash Laser ionise les molécules de matrice
- 3. Les molécules d'échantillon sont ionisées par transfert de protons de la matrice:

 $MH^+ + A \rightarrow M + AH^+$ .

# **MALDI-TOF Matrix**



Dithranol

# **Matrix choices**

α-Cyano-4-hydroxy- cinnamic acid (CHCA)	Peptides<10kDa
Sinapinic Acid	Proteins >10kDa
2,5-Dihydroxybenzoic acid (DHB)	Neutral carbohydrates, Synthetic Polymers
"Super DHB"	Proteins, Glycosylated proteins
3-Hydroxypicolinic acid	Oligonucleotides
HABA	Proteins, Oligosaccharides

## **Ionization by electrospray**



## **Electrospray and nanospray sources**



Electrospray

nanospray

## "Active Beam Guide" transmission



- Bent flatapole with axial field
- Preventing neutrals and high-velocity clusters from entering the quadrupole
- Axial field along the rods improves robustness by elimination of local charging
- Same metal capillaries as Velos (also used on Q Exactive), has V stamped on outside



## Different instrumental design



## **Importance of spectral resolution**



### Natural abundance of atoms isotopes in proteins

Name	Symbol	Mass (Da)	Abundance (%)
Hydrogen	Н	1.007825	99.9885
Deuterium	Н	2.014102	0.0115
Carbon	С	12.000000	98.9300
	С	13.003355	1.0700
Nitrogen	N	14.003074	99.6320
	N	15.000109	0.3680
Oxygen	0	15.994915	99.7570
	0	16.999132	0.0380
	0	17.999160	0.2050
Phosphorus	Р	30.973762	100.0000
Sulfur	S	31.973762	94.9300
	S	32.971458	0.7600
	S	33.967867	4.2900
	S	35.967081	0.0200



# Resolution and mass accuracy



2398 2400 2402 2404 2406 2408 m/z

Poor resolution High mass accuracy



High resolution Poor mass accuracy



High mass accuracy

High resolution makes it easier to achieve high mass accuracy – but high mass accuracy does not necessarily require high resolution! High resolution is only mandatory to avoid overlapping peaks.

## Quadrupole analysers





 $\varphi$ 0=*U*-*V*.cos(2 $\pi$ *ft*)

 $\varphi = \varphi 0. (x^2 - y^2)/r0^2$ 



# Isolation Width: Full MS to 1 amu (MRFA)



## Different instrumental design



Trappe tridimensionnelle (Paul)





Trappe linéaire (double pression)

# the orbitrap cell





$$\omega_z = \sqrt{\frac{k}{m/z}}$$
### **Developpement of the orbitrap family**



### Instrumentations



# MALDI-TOF/TOF





# Samples on MALDI plate



# Time of flight – principles (TOF)



Remember : Mass of an ion is measured in the Dalton units !

# Start !



# lons in the time of flight (TOF)



**Increasing MW** 

lons in the detector



# Ions analysis in linear mode



Electric field : Ec=  $qU = 1/2 mV^2$  Identical for all ions

(V=L/t L : tube lenght)

 $\Rightarrow$  Simple relation t<sup>2</sup>= mL<sup>2</sup>/2qU = Constante x m/z

Light Corrections :

 $t^2 = Am^2 + Bm + C$  (A : initial desorption Ec

C: Extraction Delay)

=> Simple Quadratic equation

## Ions analysis in reflectron mode



**Reflectron TOF** 



Reflectron : 2 effects on resolution :

- Increasing flight path (better separation of particles of different masses) (equivalent 3m flight tube)
- Focusing effet for particles with same mass

### **Key questions in proteomics**

- What is the protein content of my biological sample?
   => problem of identification
- What is the abundance of my protein of interest?
   => quantification problem
- Relative question: What are the protein abundance variations of the proteomes studied?
- What are the partners of my protein of interest?
- Are there any signature proteins related to a particular biological process?

=> biomarkers identifications and quantifications

# Ion precursor selection

4700 Reflector Spec #1 MC[BP = 1664.6, 132]



Mass (m/z)

# MS/MS fragmentation for peptides



# MS/MS fragmentation for peptides

### DISSOCIATION INDUITE PAR COLLISION (CID) HIGHER ENERGY COLLISIONAL DISSOCIATION (HCD) ELECTRON TRANSFER DISSOCIATION (ETD)



### MS/MS spectrum of the precursor 1362.44 m/z

4700 MS/MS Precursor 1362.44 Spec #1 MC[BP = 1207.3, 382]





<u>Alanine</u>	A, Ala	71.079
<u>Arginine</u>	R, Arg	156.188
<u>Asparagine</u>	N, Asn	114.104
Aspartic acid	D, Asp	115.089
<u>Cysteine</u>	C, Cys	103.145
<u>Glutamine</u>	Q, Gln	128.131
<u>Glutamic acid</u>	E, Glu	129.116
Glycine	G, Gly	57.052
<u>Histidine</u>	H, His	137.141
<u>Isoleucine</u>	I, lle	113.160
<u>Leucine</u>	L, Leu	113.160
<u>Lysine</u>	K, Lys	128.17
<u>Methionine</u>	M, Met	131.199
<u>Phenylalanine</u>	F, Phe	147.177
Proline	P, Pro	97.117
<u>Serine</u>	S, Ser	87.078
<b>Threonine</b>	T, Thr	101.105
<u>Tryptophan</u>	W, Trp	186.213
<b>Tyrosine</b>	Y, Tyr	163.176
Valine	V, Val	99.133

## MS/MS spectra interpretation



Table 1			
lon	m/z	Neutral loss (from previous ion in the series)	Amino Acid Residue
Precursor [M+H] <sup>+</sup>	540		
У <sub>4</sub>	409	131	М
<b>y</b> <sub>3</sub>	246	163	Y
У <sub>2</sub>	189	57	G
<b>y</b> <sub>1</sub>	118	71	A
<i>b</i> <sub>4</sub>	423	117 (99+18)	V
<i>b</i> <sub>3</sub>	352	71	А
<i>b</i> <sub>2</sub>	295	57	G
b <sub>1</sub>	132	163	Y
<i>a</i> <sub>4</sub>	395?		
a <sub>3</sub>	324		
a <sub>2</sub>	267		
a <sub>1</sub>	104		

MYGAV User AA Formula 1: C2 H3 N1 O1 Elemental Composition: C24 H38 N5 O7 S1 MH+1(av) MH+1(mono) 540.6627 540.2486 [-] Main Sequence Ions

			У
1	М	5	
2	Y	4	409.2082
3	G	3	246.1448
4	А	2	189.1234
5	V	1	118.0863
	1 2 3 4 5	1 M 2 Y 3 G 4 A 5 V	1 M 5 2 Y 4 3 G 3 4 A 2 5 V 1

http://www.sepscience.com/Information/Archive/MS-Solutions/246-

### **Current post-translational modifications (PTMs)**

Acids &	Pyroglutamic acid (Q)	-17.0306	Deamidation (Q/N)	+0.9847
amides (E/D/Q/N)	Carboxylation (E/D)	+44.0098		

Hydroxyl groups (S/T/Y)	Phosphorylation	+79.9799	Sulphation	+80.0642
-------------------------------	-----------------	----------	------------	----------

	Pentoses	+132.1161	Deoxyhexoses	+146.1430
Carbohydrates (S/T/N)	Hexosamines	+161.1577	Hexoses	+162.1424
(3/1/14)	N-acetylhexosamines	+203.1950	Sialic acid	+291.2579

Sulphydryls	Disulphide bond	-2.0159	Oxidation	+15.9994
(0)	Cysteinylation	+119.1442	Glutathionylation	+305.3117

### **Orbitrap mass spectrometers**



# MS and MS/MS spectra generation



### **DDA versus DIA**





SIMULTANEOUS ANALYSIS: In parallel-reaction monitoring (PRM), the mass spectrometer isolates a target peptide ion, subjects it to fragmentation, and analyzes the masses of all fragment ions simultaneously.





ALL TOGETHER NOW: In data-independent acquisition (DIA), the mass spectrometer isolates all peptides that fail within a relatively wide mass window, subjects all the peptides from that window to fragmentation, and analyzes the masses of all the fragment ions simultaneously. The instrument then processes all of the peptides in each subsequent, nonoverlapping window until the entire mass range of interest has been covered.

### Data Independent Acquisition: DIA

#### (A) DIA



#### (B) WISIM-DIA



#### (C) Full MS-DIA



### Contribution of nano-HPLC



### Peptides separation by nano-LC



### Peptides separation nano-LC

• It is impossible to resolve all species in a proteomics sample using only one separation method

• Multidimensional separation - two or more independent ("orthogonal") separation techniques coupled together for the analysis of a single sample.

Separation method	Separation by:
Reversed phase	Hydrophobicity
Ion exchange, IsoElectroFocusing (IEF)	Net charge, Isoelectric point
Size exclusion, SDS Gel Electrophoresis	Size, molecular weight
Affinity chromatography	Specific functional groups

# Total ion current (TIC) Hela tryptic digest (0.5 $\mu$ g of total proteins)



$$R = \frac{2(t2 - t1)}{(w2 - w1)}$$

with  $t1 \mbox{ and } t2 \mbox{ the retention time and } w1 \mbox{ and } w2 \mbox{ peak widths}$ 

at mid-height



# 90000 MSMS in 2h gradient (C18 RPC)



### **Proprietary MS data formats**

Company	Extension	File type
Agilent	D (folder)	Agilent MassHunter, Agilent ChemStation, or
Bruker	.D (loider)	Bruker BAF/YEP/TDF data format
Agilent/Bruker	.YEP	instrument data format
Bruker	.BAF	instrument data format
Bruker	.FID	instrument data format
Bruker	.TDF	timsTOF instrument data format
ABI/Sciex	.WIFF	instrument data format
ABI/Sciex	.t2d	4700 and 4800 file format
Waters	.PKL	MassLynx peak list format
Thermo	D A1A/*	Thermo Xcalibur
PerkinElmer	RAW	PerkinElmer TurboMass
Micromass**/Waters	.RAW* (folder)	Waters MassLynx
Chromtech		Finnigan ITDS file format; MAT95 instrument
Finnigan***	.DAT	data format
VG		MassLab data format
Finnigan***	.MS	ITS40 instrument data format
Shimadzu	.QGD	GCMSSolution format
Shimadzu	.qgd	instrument data format
Shimadzu	.lcd	QQQ/QTOF instrument data format
Shimadzu	.spc	library data format
Bruker/Varian	.SMS	instrument data format
Bruker/Varian	.XMS	instrument data format
ION-TOF	.itm	raw measurement data
ION-TOF	.ita	analysis data
Physical Electronics/ULVAC-PHI	.raw*	raw measurement data
Physical Electronics/ULVAC-PHI	.tdc	spectrum data

# **Open MS data formats**

#### JCAMP-DX

This format was one of the earliest attempts to supply a standardized file format for data exchange in mass spectrometry. JCAMP-DX was initially developed for infrared spectrometry. JCAMP was officially released in 1988. JCAMP was found impractical for today's large MS data sets, but it is still used for exchanging moderate numbers of spectra.

#### **ANDI-MS or netCDF**

The Analytical Data Interchange Format for Mass Spectrometry is a format for exchanging data. ANDI was initially developed for chromatography-MS data and therefore was not used in the <u>proteomics</u> gold rush where new formats based on <u>XML</u> were developed.

#### mzData

mzData was the first attempt by the <u>Proteomics Standards Initiative</u> (PSI) from the <u>Human Proteome Organization</u> (HUPO) to create a standardized format for Mass Spectrometry data. This format is now deprecated, and replaced by mzML. **mzXML** 

mzXML is a <u>XML</u> (eXtensible Markup Language) based common file format for <u>proteomics</u> mass spectrometric data. This format was developed at the Seattle Proteome Center/Institute for Systems Biology while the HUPO-PSI was trying to specify the standardized mzData format, and is still in use in the proteomics community.

#### mzML

As two formats (mzData and mzXML) for representing the same information is an undesirable state, a joint effort was set by HUPO-PSI, the SPC/ISB and instrument vendors to create a unified standard borrowing the best aspects of both mzData and mzXML, and intended to replace them. The first specification was published in June 2008. This format was officially released at the 2008 <u>American Society for Mass Spectrometry</u> Meeting, and is since then relatively stable with very few updates. On 1 June 2009, mzML 1.1.0 was released. There are no planned further changes as of 2013.

### Saving data and servers



# **Search engine**



# Search engines and validation of peptides and proteins identifications

 $FDR (\%) = \frac{(number of false positive peptides) X 2}{total number of peptides (positives + false positive)}$ 











**Bioinformatics Solutions Inc.** 

### Critical importance of mass accuracy for database searches

Expressed as Da or as ppm (10 ppm = 0,001%1 ppm = 0,0001%)



Trypsin Produced Peptide Molecular Weight (u)

Figure 1. All possible unique peptide molecular weights after digestion of all yeast proteins in the National Center for Biotechnology Information at a mass accuracy of 0.1, 1.0, and 10.0 ppm.

### A database search engine : Mascot

Home Mascot	database search Products Technic	al support	ning News Blog Contact		
Access Masset C	anver   Database search help				
Mascot database sear	reh > Access Mascot Server > MS/MS Jons Se	arch			
MASCO	T MS/MS Ions Searc	h		Λ	MATRIX SCIENCE
Your name		Email			
Search title	[		]		
Database(s)	Invertebrates_EST Human_EST	Enzyme	Trypsin 🔻		
	Fungi_EST	Allow up to	1 missed cleavages		
	SwissProt 🔽	Quantitation	None	<b>*</b>	
Taxonomy	All entries		•		
Fixed modifications	Display all modifications	> <	Acetyl (K) Acetyl (N-term) Acetyl (Protein N-term) Amidated (C-term) Amidated (Protein C-term) Ammonia-loss (N-term C)		
Variable modifications	none selected	>	Biotin (K) Biotin (N-term) Carbamidomethyl (C) Carbamyl (K) Carbamyl (N-term)	*	
Peptide tol. $\pm$	1.2 Da ▼ #13 <sub>C</sub> 0 ▼	MS/MS tol. ±	0.6 Da 🔻		
Peptide charge	2+ 💌	Monoisotopic	Average		
Data file	Parcourir Aucun fichier sélectionné.				
Data format	Mascot generic 🔻	Precursor	m/z		
Instrument	Default	Error tolerant			
Decoy		Report top	AUTO 🔻 hits		
	Start Search		Reset Form		

### **MASCOT MS/MS Ions Search**

Your name		Email		1
Search title				
Database(s)	Invertebrates_EST Human_EST Fungi_EST Environmental_EST	Enzyme Allow up to	Trypsin   Trypsin Trypsin  Trypsin Trypsi	
	SwissProt 💌	Quantitation	None	•
Taxonomy	All entries		]	
Fixed modifications	All entries Archaea (Archaeobacteria) Eukaryota (eucaryotes) Alveolata (alveolates) Plasmodium falciparum	n (malaria parasite)	Acetyl (K) Acetyl (N-term) Acetyl (Protein N-term) Amidated (C-term)	* III
Variable modifications	Other Alveolata Metazoa (Animals) Caenorhabditis elegan Drosophila (fruit flies) Chordata (vertebrates bony vertebrates lobe-finned fish a	s and relatives)	Amidated (Protein C-term) Ammonia-loss (N-term C) Biotin (K) Biotin (N-term) Carbamidomethyl (C) Carbamyl (K) Carbamyl (N-term)	•
Peptide tol. ±	Mammalia (ma Primates Homo sa	ammals)	0.6 Da ▼	
Peptide charge	Other pr	imates	Average	
Data file	Rodentia (R	Rodents)		
Data format			m/z	
Instrument	Default 👻	Error tolerant		
Decoy		Report top	AUTO 🔻 hits	
	Start Search		Reset Form	

# Search engine output formats

File name	File content
Processed peak lists	Heavily processed form of mass spectrometry data, usually derived from raw data files via various (semi-) automatic steps, e.g.: centroiding, deisotoping and charge deconvolution. These files are formatted in plain text, with typical formats like <b>dta nkl ms2</b> or <b>mgf</b>
Search engine outpu	These files contain the data and metadata generated by the software (called search engines)
files	used for performing the identification and quantification of peptides and proteins. <b>Each</b> search engine has its own specific output file format. The outputs are typically formatted in either plain text or XML. <u>mzIdentML</u> - provides a common format for the export of identification results from any search engine. <u>mzQuantML</u> - provides a common format for the export of quantification results from any search engine. <u>mzTab</u> - provides a common format for the export of quantification results from any search engine. <u>mzTab</u> - represents both identification and basic quantification results. To allow a full representation of the processed results in the PRIDE database and in the PX tool, the search engine output files need to be converted to PRIDE XML. <u>PRIDE Converter</u> and <u>PRIDE Converter 2</u> are the two tools developed by the PRIDE team to make this conversion
Protein/peptide	Proteomics mass spectra can be matched to peptides or proteins, resulting in identifications
identifications	for those spectra. Typically a spectrum is considered to have been identified if the score attributed to a peptide or protein match qualifies against an <i>a priori</i> or <i>a posteriori</i> defined threshold. In the case of fragmentation spectra, the initial identification will consist of a peptide sequence; subsequent steps will derive a list of proteins from the identified peptides. The protein assembly step can be a discernible process with its own input and output files, or it can be implicit in the overall identification software.
### 31700 MS/MS spectra interpreted!!!!



Sequence: VIELFSVCTNEDPK, C8-Carbamidomethyl (57.02146 Da) Charge: +2, Monoisotopic m/z: 825.90680 Da (+0.95 mmu/+1.15 ppm), MH+: 1650.80632 Da, RT: 63.18 min, Identified with: Sequest HT (v1.3); XCorr:4.48, Ions matched by search engine: 0/0 Fragment match tolerance used for search: 0.5 Da Fragments used for search: b; b-H<sub>2</sub>O; b-NH<sub>3</sub>; y; y-H<sub>2</sub>O; y-NH<sub>3</sub>

Protein references (1):

- Lymphokine-activated killer T-cell-originated protein kinase OS=Homo sapiens GN=PBK PE=1 SV=3 - [TOPK\_HUMAN]

## 5448 identified proteins

-	100			Q96KB5	Lymphokin	e-activate	d killer T-cell	originated protein ki	nase O5=Ho…	41.78	60.87 %	1		12	12	13	32	2 3
	Ē	尹	A2	2 Sequer	nce	# PSMs	# Proteins	# Protein Groups	Protein Grou	p Accessions	Modifi	ications	ΔCn	q-Value	e / P	EP	XCorr	Charge
						=	=	=					=	=	=	=		= =
E	•	1	0	IcDVGVSLPLDE	IMTVTDPE	1	1	1	Q96KB5		C2(Carbamid	omethyl); C22	0.0000		0	.17e-07	5.1	.0 3
1	Đ	2	•	VIELFSVcTNEDP	ĸ	1	1	1	Q96KB5		C8(Carbamid	ometh <mark>y</mark> l)	0.0000		0 !	i.96e-07	4.4	8 2
E	<b>.</b>	3		SVLcSTPTINIPAS	PFMQK	1	1	1	Q96KB5		C4(Carbamid	omethyl)	0.0000		0 3	.75e-05	3.2	.4 3
1	Đ	4	•	AFTEANDGSLcL	AMEYGGEK	1	1	1	Q96KB5		C11(Carbamic	domethyl)	0.0000		0 9	0.89e-05	3.2	2 2
E	•	5	•	INPICNDHYR		1	1	1	Q96KB5		C5(Carbamid	omethyl)	0.0000		0 0	.000356	3.0	9 3
E	Ð	6	•	SLHHPNIVGYR		1	1	1	Q96KB5				0.0000		0	0.00076	2.8	6 3
E	•	7	9	SLNDLIEER		1	1	1	Q96KB5				0.0000		0	0.00187	2.8	5 2
E	Ð	8	•	ASQDPFPAAIILK		1	1	1	Q96KB5	Q96KB5		0.0000		0	0	0.00016	2.7	1 2
E	•	9	0	TFDESDFDDEAY	YAALGTRP	1	1	1	Q96KB5		Q32(Deamida	ted)	0.0000	(	0.001	0.0153	3.3	4 4
l	Ð.	10	•	TFDESDFDDEAY	EAYYAALGTRP		1	1	Q96KB5		N23(Deamida	ted); Q32(De	0.0000	(	.001	0.0198	2.40	0 3
6	<b>-</b>	11	•	VALNMAR		1	1	1	Q96KB5		_		0.0000	(	0.001	0.00852	2,1	4 2
E	Ð	12	•	EAVEENGVITDK		1	1	1	. Q96KB5				0.0000		).004	0.048	2.7	8 2
E	•	13	•	DRPSAAHIVEALI	ETDV	1	1	1	Q96KB5		ļ		0.0000		.006 0.0779		3.5	8 3
	团			Accession			Descri	ption		Score	Coverage	# Proteins	# UniqueP	eptides⊽	# Peptides	# PSMs	# AAs	MW [kDa
÷.	101	Г	1	A0AVT1	Ubiquitin-li	ke modifie	er-activating	enzyme6 OS=Homo	sapiens GN=	43.86	14.83 %	1		12	12	14	105	2 11
+	102	Г		000116	Alkyldihydi	roxyaceto	nephosphate	synthase, peroxisoma	al OS=Homo	40.54	25.08 %	1		11	11	11	. 65	3 7.
÷.	103	Г		Q12802	A-kinase ar	ichor prote	ein 13 OS=Ho	mo sapiens GN=AK	AP13PE=1	32.11	9.14 %	1		11	11	13	281	3 30
+	104	Г		043684	Mitotic che	ckpoint pr	oteinBUB3 0	S=Homo sapiens GN	I=BUB3 PE=	38.40	44.51 %	1		11	11	11	. 32	3 3
÷	105	Г		060832	H/ACA ribo	nucleopro	tein complex	subunit 4 OS=Homo	sapiens GN	32.86	24.71 %	1		11	11	11	. 514	ł 5
+	106	Г		P19525	Interferon-	induced, d	ouble-strand	led RNA-activated pro	otein kinase	34.26	24.68 %	1		11	11	11	. 55	1 63
÷	107	Г		Q8N3D4	EH domain	binding p	rotein 1-like p	protein 1 OS=Homos	sapiens GN=	43.89	11.36 %	1		11	11	13	152	3 16
+	108	Г		P60228	Eukaryotic	translatio	ninitiationfac	ctor 3 subunit EOS=H	Homo sapie	41.87	32.13 %	1		11	11	12	. 44	5 5
÷	109	Г	11 3	P62495	Eukaryotic	peptide ch	iain release fa	actor subunit 105=H	lomo sapien	53,24	37.30 %	1		11	11	16	43	7 41
+	110	Г		P15170	Eukaryotic	peptide ch	iain release fa	actor GTP-binding su	ibunit ERF3A	45.47	36.27 %	1		11	11	12	. 49	) 5
•																		

# History of standard identifications

Mass Spectometer	HPLC	Gradient Time (min)	Column	Species	Mascot (Protein/Peptide)	Sequest (Protein/Peptide)
	EasynLC Proxeon	75	10	Saccharomyces cerevisae	972/3912	1111/4884
		120	25	Saccharomyces cerevisae	1234/5245	1402/5948
Valaa	KSLU	240	25	Saccharomyces cerevisae	1198/4583	1422/6072
velos	<b>Factor (C 4000</b>	120		Saccharomyces cerevisae	1505/8317	1638/8339
		120	50	Candida glabrata	1598/7097	
	Easynee 1000	240	50	Saccharomyces cerevisae	2135/7337	
		240		Candida albicans	2049/7676	2135/7337
Fusion	Eacypl C 1000	120	FO	Saccharomyces cerevisae	2202/16726	2350/11897
FUSION	Easynet 1000	120	50	Candida albicans		



## **Key questions in proteomics**

- What is the protein content of my biological sample?
  => problem of identification
- What is the abundance of my protein of interest?

### => quantification problem

- Relative question: What are the protein abundance variations of the proteomes studied?
- What are the partners of my protein of interest?
- Are there any signature proteins related to a particular biological process?

=> biomarkers identifications and quantifications

## **Quantitative proteomics**

- Relative quantification
  - Stable isotopes labelling
  - Label-free
  - Metabolic labeling
- Absolute quantification

### **Quantitative proteomics**



### **Quantitative proteomics in bottom-up**



### Advantages/Limitations:

### Label-free:

- Metabolic Labeling (SILAC, <sup>14</sup>N/<sup>15</sup>N <sup>13</sup>C labeling)
- Chemical labeling (TMT,ITRAQ)



### **Quantitative proteomics: label-free**



### Advantages/Limitations:

### Label-free:

- Simplicity
- Number of identifications
- Reproductibility between runs
- Number of samples to run

Review for Label-free and yeasts: Leger et al. Methods Mol Biol (2016)



## **Quantitative proteomics without labeling**

### Quantification label-free basée sur les intensités MS

**B:** alignment

A: LC-MSMS



## **Quantitative proteomics without labeling : results**

#### **Experiment Design**



#### Proteins

Protein building options

#### Protein grouping Group similar proteins

#### Protein quantitation Using only features with no protein conflicts

Accession	Peptides	Score	Anova	Fold	Tags	Description	scription						ormalised A	bundances				
			(P)*									WT	1003	1006	1215	1443		
HSP71_YEAST	57 (18)	4959.38	5.84e-005	2.40		Heat shock protein SSA1 OS=Saccharon	nyces cerevis	siae (strain ATCC	204508 / S288c)	GN=SSA1 PE=1 SV	=4	1.23e+007	7.42e+006	9.72e+006	9.87e+006	5.13e+006		
EF2_YEAST	69	4650.11	7.26e-004	2.16		Elongation factor 2 OS=Saccharomyces	ngation factor 2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GN=EFT1 PE=1 SV=1 3.40							2.89e+007	3.28e+007	1.58e+007		
FAS1_YEAST	74 (71)	4506.21	9.72e-003	2.33		Fatty acid synthase subunit beta OS=Sa	v acid synthase subunit beta OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GN=FAS1 PE=1 SV=2 1.0							8.51e+006	1.01e+007	1.53e+007		
EF3A_YEAST	58 (44)	3816.91	7.06e-006	3.32		Elongation factor 3A OS=Saccharomyce	ngation factor 3A OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GN=YEF3 PE=1 SV=4 2.4							2.33e+007	2.72e+007	8.66e+006		
METE_YEAST	46	3373.13	1.85e-006	13.40		5-methyltetrahydropteroyltriglutamate 204508 / S288c) GN=MET6 PE=1 SV=4	ethyltetrahydropteroyltriglutamatehomocysteine methyltransferase OS=Saccharomyces cerevisiae (strain ATCC 4508 / S288c) GN=MET6 PE=1 SV=4							4.34e+006 5.55e+006 3.77e+006 5.16e+				
HS104_YEAST	53	3190.19	6.84e-004	2.29		Heat shock protein 104 OS=Saccharo	Accessi	ion HSP71_YE	AST						6	3.51e+006		
HSP75_YEAST	40 (1)	3062.55	1.21e-006	28.16		Heat shock protein SSB1 OS=Sacchard									5	1.05e+004		
HSP7F_YEAST	39 (32)	2658.69	2.58e-004	2.01		Heat shock protein homolog SSE1 OS	escripti	on Heat shock or	otein SSA1 05=5	accharomyces ce	revisiae (strain	ATCC 204508	3 / 5288c) G	N=SSA1 PF=1	1 SV=4 6	3.50e+006		
ENO1_YEAST	31 (15)	2367.12	6.07e-005	2.19		Enolase 1 OS=Saccharomyces cerevis	Peptid	les 57 (18)		,					6	1.46e+007		
ATPA_YEAST	32	2341.09	3.17e-006	2.59		ATP synthase subunit alpha, mitocho SV=5	Sco	ore 4959.38							6	3.66e+006		
SYLC_YEAST	37	2176.12	1.52e-006	2.01		LeucinetRNA ligase, cytoplasmic OS	Fc	old 2.40							6	1.82e+006		
HXKA_YEAST	29 (28)	2162.35	3.17e-004	2.88		Hexokinase-1 OS=Saccharomyces cer	1	Anova p-value	e ≤ 0.05						7	4.61e+006		
ALDH6_YEAST	30	2091.58	4.85e-004	2.15		Magnesium-activated aldehyde dehyd GN=ALD6 PE=1 SV=4	1	Max fold chan	ge ≥ 2						6	2.50e+006		
ATPB_YEAST	28	2015.82	4.45e-006	2.39		ATP synthase subunit beta, mitochon SV=2		WT	1003	1006	1215	1443	3		6	4.05e+006		
G3P1_YEAST	31 (21)	1986.15	8.75e-005	4.16		Glyceraldehyde-3-phosphate dehydrog PE=1 SV=3	170	<b>F</b>							6	1.79e+007		
HSP74_YEAST	26 (12)	1750.55	0.04	2.68		Heat shock protein SSA4 OS=Sacchar	-	-		Ť	T				5	5.24e+005		
PUR92_YEAST	28 (22)	1725.94	6.21e-007	7.07		Bifunctional purine biosynthesis prote PE=1 SV=2	-		-	Ŧ	1				6	9.63e+006		
ADH1_YEAST	24 (17)	1689.13	5.88e-004	2.62		Alcohol dehydrogenase 1 OS=Sacchar	16.5 —		<u>1</u>						7	1.03e+007		
HSP26_YEAST	18	1538.64	2.83e-006	2.31		Heat shock protein 26 OS=Saccharom	-					1			7	8.43e+006		
SAHH_YEAST	27	1535.76	2.79e-006	3.51		Adenosylhomocysteinase OS=Sacchar	-					► 4			6	1.31e+007		
PCKA_YEAST	20	1515.31	3.42e-009	9.67		Phosphoenolpyruvate carboxykinase [ SV=2	16.0	4					P		6	6.25e+005		

## **Quantitative proteomics with labeling**



### **Quantitative proteomics: metabolic labeling**



### Advantages/Limitations:

### □ <u>SILAC</u>:

- Multiplexing
- Reproductibility
- 2 peaks instead of 1 to analyze by the MS (for 2 samples)
- Less identifications
- Partial labeling
- Arginine/proline conversion (use of mutants)
- Trypsin exclusively

### $\Box \frac{14N/15N - 13C \text{ labeling}}{13C \text{ labeling}}$

- Multiplexing
- Reproductibility
- 2 peaks instead of 1 to analyze by the MS (for 2 samples)
- Less identifications and quantifications
- Partial labeling
- Variable mass shift between heavy and light forms



# SILAC approaches



### **Quantitative proteomics: chemical labeling**



### Advantages/Limitations:

### □ Chemical labeling (TMT, ITRAQ)

- Multiplexing (until 11plex)
- Reproductibility
- Quantification in MS2 or MS3
- 1 peak instead of N (for N samples) to analyse in MS
- Amount of materials for the peptide labeling
- Need of resolution in MS2 for quantifications
- Incomplete labeling
- Less identifications and quantifications



# **TMT labeling : principles**



### **Quantitative proteomics in bottom-up**



#### <sup>14</sup>N/<sup>15</sup>N **ICAT** ITRAQ, Label-free SILAC

### Advantages/Limitations:

#### □ Label-free:

- Simplicity
- Number of identifications
- Reproductibility between runs
- Number of samples to run

#### SILAC:

- Multiplexing -
- Reproductibility
- 2 peaks instead of 1 to analyze by the MS (2 samples)
- Less identifications
- Partial labeling
- Arginine/proline conversion (use of mutants)
- Trypsin exclusively

#### $^{14}N/^{15}N - ^{13}C$ labeling:

- Multiplexing 2
- Reproductibility
- 2 peaks instead of 1 to analyze by the MS (2 samples)
- Less identifications and quantifications
- Partial labeling
- Variable mass shift between heavy and light forms

#### Chemical labeling (TMT, ITRAQ)

- Multiplexing
- Reproductibility
- 1 peak instead of N to analyse in MS (N samples)
- Amount of materials for the peptide labeling
- Need of resolution in MS2 for quantifications
- Incomplete labeling
- Less identifications and quantifications

### Metabolic

### labeling

## **Quantitative proteomics without labeling : export**

Progenesis QI

																		tor pro	iconnes.	
1										0			Normalize	d abundance	2					
2													Sain						Patient	
3	Accession	Peptide cou	Unique per (	Confidence	Anova (p)	q Value	Max fold ch	Power	Highest m	Lowest mea	Mass	Description	1845007-F1	1845007-F3	1845007-F5	1845007-F7	1845007-F9	1845007-F11	1845007-F2	1845007-F4
4	P40197	12	12	545.23	2.48E-07	4.74E-05	32.042418	1	Patient	Sain	60.921	Platelet glycoprotein V	OS 1447.8857	898.47877	2114.249	3517.982	2506.9091	1186.7152	33178.605	73995.78
5	P02776	2	2	134.77	2.63E-07	4.74E-05	78.817355	1	Patient	Sain	10.838	Platelet factor 4 OS=Ho	nc 3812.4369	3755.8358	1044.3911	2939.4867	3862.0883	1110.5549	333829.66	68071.51
6	Q13201	6	6	221.4	5.33E-07	6.40E-05	72.663027	1	Patient	Sain	138.023	Multimerin-1 OS=Homo	sa 160.48528	939.93933	155.7663	732.57482	572.39757	196.60688	75519.303	23299.12
7	P04114	336	334	28302.18	7.99E-06	0.0006593	2.1384481	1	Patient	Sain	515.283	Apolipoprotein B-100 O	S= 14117253	10601958	8472023.6	9982572.2	10056625	11898407	24415094	1744463:
8	P07996	42	42	2678.71	9.16E-06	0.0006593	143.08362	1	Patient	Sain	129.3	Thrombospondin-1 OS=	Hc 11604.367	10346.75	4059.3393	5652.5533	2121.1343	2367.1543	2303007.2	83175.08
9	Q15485	7	7	289.57	1.42E-05	0.0007087	24.427918	0.9999997	Patient	Sain	33.98	Ficolin-2 OS=Homo sap	ier 8778.176	6132.5206	10104.107	8194.6312	8690.2929	1737.9715	185819.2	105024.9
10	P10720	3	3	208.63	1.49E-05	0.0007087	36.552808	0.9999997	Patient	Sain	11.545	Platelet factor 4 variant	0 32881.787	11758.269	1451.6395	5448.2604	4187.5362	4196.5766	546497.96	239272.0
11	Q12884	2	2	70.47	1.58E-05	0.0007087	Infinity	0.9999996	Patient	Sain	87.657	Prolyl endopeptidase F	AP C	0	0	0	0	0	961.55592	106.477
12	Q15061	1	1	3.67	3.71E-05	0.0014832	23.811179	0.9999905	Sain	Patient	74.843	WD repeat-containing	orc 567513.12	751475.75	852125.74	1189728.8	625225.18	78135.037	46681.126	36585.06
13	P04075	8	8	371.85	4.58E-05	0.0016488	4.2937733	0.9999814	Patient	Sain	39.395	Fructose-bisphosphate	al 33219.801	26234.171	28730.699	26696.908	33816.665	32024.353	128602.25	168571.
14	P09486	10	9	463.23	6.25E-05	0.0020451	6.1746973	0.999953	Patient	Sain	34.61	SPARC OS=Homo sapier	s 9522.5101	37758.131	36721.019	20388.641	15117.423	28228.93	299004.24	97804.24:
15	P10124	1	1	70.16	7.11E-05	0.002134	272.44302	0.9999321	Patient	Sain	17.641	Serglycin OS=Homo sap	iei 67.740323	0	958.26875	53.15204	160.31231	238.84011	105180.09	42246.24:
16	P02775	6	6	388.98	8.21E-05	0.0022557	28.012451	0.9998996	Patient	Sain	13.885	Platelet basic protein C	S= 61607.9	109352.83	105910.89	67216.894	60865.635	22752.188	3524260.5	1692399.
17	Q9H1K0	2	2	12.94	8.77E-05	0.0022557	1.8919044	0.9998799	Patient	Sain	88.815	Rabenosyn-5 OS=Homo	sa 871721.79	1194024.5	1103071.3	1121288.3	1020557.4	1361492.9	1506333.1	1757466.
18	P35542	4	4	338.41	0.0001236	0.0029659	16.656374	0.9997122	Patient	Sain	14.737	Serum amyloid A-4 prot	eii 192222.76	102064.74	9416.0169	8023.3014	46690.651	107524.48	1543185.2	1741696.
19	P80188	6	6	223.58	0.0001847	0.0041561	9.1194461	0.9992657	Patient	Sain	22.574	Neutrophil gelatinase-	as 2265.4484	1473.9176	6203.72	3676.0015	7827.3304	4603.3796	66633.817	26485.80
20	P02144	4	4	209.23	0.0002392	0.0050651	6.5032553	0.9987201	Patient	Sain	17.173	Myoglobin OS=Homo sa	pi 2754.3333	2223.1201	1035.6898	1813.5104	1462.164	5472.3528	17977.389	20813.2
21	P05067	5	5	179.76	0.000297	0.0059397	18.947351	0.9980148	Patient	Sain	86.888	Amyloid beta A4 protei	n C 408.20926	53.510036	338.118	494.28658	258.47482	516.31147	8561.0101	2161.775
22	Q9NPH3	7	7	223.36	0.0003417	0.0064734	2.9534965	0.9973949	Patient	Sain	65.377	Interleukin-1 receptor a	cc 19269.326	23550.392	17918.705	19071.463	29165.24	20448.453	74326.28	82743.30
23	P22352	7	7	322.73	0.0005632	0.0101356	2.3655577	0.9936247	Patient	Sain	25.537	Glutathione peroxidase	3 356078.09	500176.63	411199.92	354267.54	608490.2	620677.21	1139291.1	1214566.0
24	A0A075B610	1	1	30.88	0.0005981	0.0102519	15.884721	0.9929515	Sain	Patient	12.806	Immunoglobulin lambo	la 14017.761	25223.891	6493.2483	70640.84	15600.774	36585.067	4641.3232	1487.298
25	P05155	33	33	2513.9	0.0007389	0.0120898	5.4023431	0.9900925	Patient	Sain	55.119	Plasma protease C1 inh	ib 741421.19	592478.75	377555.54	465885.04	2331779.9	7791080.5	11109177	1051176
26	A0A0C4DH2	2	2	100.38	0.0013344	0.0208833	3.8865369	0.9766266	Sain	Patient	12.999	Immunoglobulin heavy	va 50500.146	64330.439	38938.111	121804.39	27881.723	32180.678	24057.435	17302.86
27	P14780	6	6	207.75	0.0014988	0.0221418	62.066206	0.972746	Patient	Sain	78.408	Matrix metalloproteina	se 794.97907	136.39171	262.24899	313.84328	0	555.64619	58928.664	9636.858
28	P02649	27	27	1941.9	0.0015378	0.0221418	2.4710215	0.971824	Patient	Sain	36.132	Apolipoprotein E OS=Ho	om 2552396.1	1536331.8	853676.88	1079240.3	1188651.7	1327575.2	2857655.7	2177433.
29	Q3C1V8	1	1	14.2	0.0019728	0.0268284	5.551993	0.9615339	Patient	Sain	25.917	Brain-specific homeobo	119.76184	56.50442	16.821931	8.5075688	3888.8817	85.190432	6077.0842	3199.583
30	P02652	11	11	995.34	0.0020124	0.0268284	2.4014067	0.9606031	Patient	Sain	11.168	Apolipoprotein A-II OS=	Hc 34056410	26771849	14632439	15663194	42268641	26890744	89512485	4323663
31	P08571	12	12	937.27	0.0025308	0.0320335	1.6971067	0.9485492	Sain	Patient	40.051	Monocyte differentiatio	n 797874.17	434080.26	499432.28	477652.53	733837.28	418725.29	352767.33	318079.3
32	P26927	31	31	1222.76	0.0025808	0.0320335	3.3123536	0.9474046	Patient	Sain	80.268	Hepatocyte growth facto	or- 190652.76	43028.557	155598.93	60550.701	75682.634	141408.77	141623.19	380083.0
33	P02655	6	6	819.16	0.0030504	0.0361789	4.7206762	0.9368237	Patient	Sain	11.277	Apolipoprotein C-II OS=	Hc 1281811.8	751583.4	312951.49	1013499	603757.76	1691499.6	4859804.1	1376230
34	P02671	8	8	369.69	0.0031158	0.0361789	191.8384	0.9353762	Patient	Sain	94.914	Fibrinogen alpha chain	0 1792.4021	4843.2609	2616.5938	746.39308	685.49376	8280.2447	1254362.7	107899
35	P02763	17	17	1378.36	0.0036234	0.0407586	2.8533872	0.924364	Sain	Patient	23.497	Alpha-1-acid glycoprote	in 67476432	40320887	40796528	53919933	106057189	35895348	25642029	2274357
36	Q14831	1	1	23.81	0.0038979	0.0425178	2.9788784	0.9185746	Sain	Patient	102.185	Metabotropic glutamat	er 26519.187	83446.172	72384.114	34456.805	83227.769	36550.192	8908.5356	31759.884
37	P02647	32	32	2367.65	0.0040205	0.0425648	2.2688435	0.9160271	Patient	Sain	30.759	Apolipoprotein A-I OS=	lo 105663566	161836184	96430549	75237801	158864474	104736598	166481100	27802701:
38	P01876	21	21	1557.26	0.0044316	0.0455765	3.5420267	0.9076475	Sain	Patient	37.631	lg alpha-1 chain C regio	n 10958465	3390608.1	19371147	11129440	8232536	4863588.4	3403586.2	5212718.
39	Q9UNW1	8	8	227	0.005259	0.0525841	1.7900311	0.8915219	Sain	Patient	55.016	Multiple inositol polyp	ho 62640.486	55052.459	58667.71	30459.856	63293.849	79838.921	34467.455	30358.52
40	Q16853	2	2	81.52	0.0054293	0.0528194	6.1436713	0.8883207	Sain	Patient	84.568	Membrane primary ami	ne 24451.336	3442.0472	3308.1744	4995.8869	4135.7996	9790.8939	236.61601	194.7495
41	P01833	8	8	219.66	0.006944	0.0656448	9.1555604	0.8614401	Sain	Patient	83.232	Polymeric immunoglob	li 14801.731	38882.249	8643.925	36538.175	31852.344	72666.846	1025.7634	2483.330:
42	P27169	28	27	2064.1	0.0071604	0.0656448	1.8486226	0.8578184	Patient	Sain	39.706	Serum paraoxonase/an	le 3861076.2	5186138.5	2149700.4	5390878.2	2346566.5	3471134.2	5925120.8	6280114.
43	P60174	1	1	28.75	0.0074	0.0656448	2.9166777	0.8538651	Patient	Sain	30.772	Triosephosphate isome	era 4225.6237	1794.3666	1066.6861	1210.1584	3775.1162	2981.76	10398.334	4675.589
44	P00736	41	39	3067.37	0.0074771	0.0656448	1.4866701	0.8526056	Sain	Patient	80.067	Complement C1r subcor	np 5434650.2	5169551.9	3906709.5	4169170.8	3458132.5	4641351.5	4547911.2	2638367.
45	P09871	37	37	2588.95	0.0085558	0.0726349	1.93603	0.835606	Sain	Patient	76.635	Complement C1s subco	mp 5789892.8	5490839.9	3882940.1	5662793.4	5033975.1	2280238.9	1956631.4	2302798.
46	A0A0B4J1V0	3	3	104.52	0.0086769	0.0726349	2.7965659	0.833766	Sain	Patient	12.917	Immunoglobulin heavy	va 92353.063	20397.701	46790.32	87239.628	43135.867	81618.911	38454.812	17117.34:
47	P01619	4	4	262.21	0.0095577	0.0781901	2.30903	0.8207663	Sain	Patient	12.549	Immunoglobulin kappa	va 409287.43	332471.99	228180.64	675002.86	220569.52	187876.28	139130.56	148976.3
48	Q08380	21	21	1485.84	0.0115602	0.0900161	2.528023	0.7934679	Sain	Patient	65.289	Galectin-3-binding prot	ei 938408.99	614190.09	1091308.6	2622296.8	1676638.8	2590031.7	640186.94	906404.5
49	P06732	9	9	314.24	0.0117011	0.0900161	5.8938011	0.7916528	Patient	Sain	43.074	Creatine kinase M-type	0: 7288.867	9691.0748	1004.0051	6516.3248	4494.7392	6004.4549	19154.379	89665.94

### **Quantitative proteomics without labeling : export**

1175			
aifMsms.txt	18-Oct-18 6:45 PM	Fichier TXT	0 Ko
allPeptides.txt	18-Oct-18 6:47 PM	Fichier TXT	63,279 Ko
📄 evidence.txt	18-Oct-18 6:44 PM	Fichier TXT	5,765 Ko
imatchedFeatures.txt	18-Oct-18 6:45 PM	Fichier TXT	0 Ko
modificationSpecificPeptides.txt	18-Oct-18 6:44 PM	Fichier TXT	2,281 Ko
msms.txt	18-Oct-18 6:44 PM	Fichier TXT	26,108 Ko
msmsScans.txt	18-Oct-18 6:45 PM	Fichier TXT	15,918 Ko
📄 msScans.txt	18-Oct-18 6:47 PM	Fichier TXT	2,211 Ko
📄 mzRange.txt	18-Oct-18 6:47 PM	Fichier TXT	95 Ko
Oxidation (M)Sites.txt	18-Oct-18 6:44 PM	Fichier TXT	125 Ko
parameters.txt	18-Oct-18 6:44 PM	Fichier TXT	2 Ko
peptides.txt	18-Oct-18 6:44 PM	Fichier TXT	2,741 Ko
📄 proteinGroups.txt	18-Oct-18 6:43 PM	Fichier TXT	1,108 Ko
summary.txt	18-Oct-18 6:44 PM	Fichier TXT	2 Ko
🔁 tables.pdf	18-Oct-18 6:45 PM	Adobe Acrobat D	40 Ko



Protein IDs Majority protein IDs Peptide counts (all) — Peptide counts (razor+unique) — Peptide counts (unique) Fasta headers — Number o 2 C1 00060W A>C1 00060W A>10 →10 →10 →>C1 00060W A translated using codon table 12 (512 amino acids) Verified ORF; (orf19.6109) Transcriptiona 3 C1 00070W A>C1 00070W A>12 -> 12 -> C1 00070W A translated using codon table 12 (362 amino acids) Verified ORF; (orf19.6105) Mevalonate dip 4 C1 00110W A>C1 00110W A>14 → 14 → 14 → 14 → >C1 00110W A translated using codon table 12 (540 amino acids) Verified ORF; (orf19.6099) Chaperonin-con 5 C1 00140W A>C1 00140W A>S -> 5 -> 5 -> C1 00140W A translated using codon table 12 (1018 amino acids) Verified ORF; (orf19.6092) Kelch repeat 6 C1 00150C A)C1 00150C A)1 ->1 ->>C1 00150C A translated using codon table 12 (622 amino acids) Verified ORF; (orf19.6091) Beta-arrestin-C1 00160C A>C1 00160C A>4 ->4 ->4 ->C1 00160C A translated using codon table 12 (400 amino acids) Verified ORF; (orf19.6090) Putative nucle 8 C1 00170W A>C1 00170W A>S -> 9 -> SC1 00170W A translated using codon table 12 (579 amino acids) Verified ORF; (orf19.6086) Putative 2-iso 9 C1 00180W A>C1 00180W A>3 -> 3 -> C1 00180W A translated using codon table 12 (200 amino acids) Verified ORF; (orf19.6085) Ribosomal prot 10 C1 00210C A>C1 00210C A>C1 00210C A>C1 00210C A translated using codon table 12 (384 amino acids) Verified ORF; (orf19.6082) Ortholog(s) ha 12 C1 00320W A>C1 00320W A>C1 00320W A>C1 00320W A>C1 00320W A translated using codon table 12 (261 amino acids) Uncharacterized ORF; (orf19.6076) Ortholo 13 C1 00330C A>C1 00330C A>C1 00330C A>C1 00330C A>C1 00330C A translated using codon table 12 (182 amino acids) Uncharacterized ORF; (orf19.6075) Putativ 14 C1 00340W A>C1 00340W A>A → 4 → 4 → >C1 00340W A translated using codon table 12 (248 amino acids) Verified ORF; (orf19.6074) Essential prot 15 C1 00380C A>C1 00380C A>7 ->7 ->>C1 00380C A translated using codon table 12 (745 amino acids) Uncharacterized ORF; (orf19.6071) Ortholo 16 C1 00400W A>C1 00400W A>7 ->7 ->>C1 00400W A translated using codon table 12 (382 amino acids) Uncharacterized ORF; (orf19.6068) Putativ 17 C1 00410C A>C1 00410C A>13 →13 →12 →>C1 00410C A translated using codon table 12 (542 amino acids) Uncharacterized ORF; (orf19.6066) Hexadec 18 C1 00420W A>C1 00420W A>7 ->7 ->>C1 00420W A translated using codon table 12 (323 amino acids) Uncharacterized ORF; (orf19.6065) RNA pol 19 C1 00440W A>C1 00440W A>11→11→11→>C1 00440W A translated using codon table 12 (478 amino acids) Uncharacterized ORF; (orf19.6063) Putativ 20 C1 00450C A>C1 00450C A>2 ->2 ->C1 00450C A translated using codon table 12 (150 amino acids) Uncharacterized ORF; (orf19.6062.3) Mitoc 21 C1 00460W A>C1 00460W A>1 ->1 ->>C1 00460W A translated using codon table 12 (106 amino acids) Verified ORF; (orf19.6062) Putative TIM23 22 C1 00480C A>C1 00480C A>A→4→4→+A→>C1 00480C A translated using codon table 12 (751 amino acids) Uncharacterized ORF; (orf19.6060) YEF3-su 23 C1 00490C A>C1 00490C A>C1 00490C A>C1 00490C A>C1 00490C A translated using codon table 12 (119 amino acids) Verified ORF; (orf19.6059) Putative gluta 24 C1 00500C A>C1 00500C A>3 -> 3 -> C1 00500C A translated using codon table 12 (342 amino acids) Uncharacterized ORF; (orf19.6058) Putativ 25 C1 00560W A>C1 00560W A>C1 00560W A>C1 00560W A>C1 00560W A translated using codon table 12 (390 amino acids) Verified ORF; (orf19.6052) Putative co-ch 26 C1 00590W A>C1 00590W A>14 →14 →14 →>C1 00590W A translated using codon table 12 (426 amino acids) Uncharacterized ORF; (orf19.6047) Transla 27 C1 00610W A>C1 00610W A>3 ->>C1 00610W A translated using codon table 12 (590 amino acids) Verified ORF; (orf19.6045) Phosphatidylse

# **Quantification output formats**

File name	File content
Protein/peptide quantifica	Protein/peptide expression values can also be obtained from an MS
tion	based proteomics experiment and then this data and metadata is used
	for performing the quantification analysis of peptides and proteins.
Metadata	A term used to describe data that provides additional information
	about a particular data set. This information can include how, when
	and where the data set was generated and what standards were used.
	In the proteomics context the addition of metadata such as peptide
	and protein identifications and quantification of their expression
	values gives meaning to a simple collection of mass spectra output
	files.

### **Targeted proteomics : PRM mode**



## **Absolute quantification**



## **Key questions in proteomics**

- What is the protein content of my biological sample?
  => problem of identification
- What is the abundance of my protein of interest?
  => quantification problem
- Relative question: What are the protein abundance variations of the proteomes studied?
- What are the partners of my protein of interest?
- Are there any signature proteins related to a particular biological process?

=> biomarkers identifications and quantifications

# **Co-immunoprecipitation**

圉		Accession	Description	Score A3	Score B3 V	Score C3
1	Г	Q13618	Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=2 -[CUL3		1172.08	547.08
2		Q86VP6	Cullin-associated NEDD8-dissociated protein 1 05=Homo	0.00	394.42	0.00
3		P62877	E3 ubiquitin-protein ligase RBX1 OS=Homo sapiens GN=R		251.21	123.68
4		P07437	Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV		199.36	136.63
5		Q9Y2M5	Kelch-like protein 20 OS=Homo sapiens GN=KLHL20 PE=		164.62	78.37
6		Q9P2N7	Kelch-like protein 13 OS=Homo sapiens GN=KLHL13 PE=		158.68	86.54
7		P68371	Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE		150.00	143.23
8		Q9P2K6	Kelch-like protein 42 OS=Homo sapiens GN=KLHL42 PE=		149.87	62.55
9		P05141	ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 P		148.12	57.72
10		Q92905	COP9 signalosome complex subunit 5 OS=Homo sapiens		142.70	29.32
11		Q99627	COP9 signalosome complex subunit 8 OS=Homo sapiens		135.68	37.43
12		P68363	Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B P	37.89	135.00	103.98
13		Q9P2J3	Kelch-like protein 9 OS=Homo sapiens GN=KLHL9 PE=1 S		131.61	110.90
14		P12236	ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 P		131.31	78.50
15		Q96M94	Kelch-like protein 15 OS=Homo sapiens GN=KLHL15 PE=		130.71	35.01
16		Q53G59	Kelch-like protein 1205=Homo sapiens GN=KLHL12 PE=		127.87	23.09
17		P49411	Elongation factor Tu, mitochondrial OS=Homo sapiens GN		112.52	119.93
18		Q9P2G9	Kelch-like protein 8 OS=Homo sapiens GN=KLHL8 PE=2 S		110.71	28.11
19		Q7L5N1	COP9 signalosome complex subunit 6 OS=Homo sapiens		106.43	25.42



KLHL12

CUL3

COPS5

(I HI 3

KLHL13

KEAP1

SPOP

Ilektra Kouranti (HEGP)

## **Key questions in proteomics**

- What is the protein content of my biological sample?
  => problem of identification
- What is the abundance of my protein of interest?
  => quantification problem
- Relative question: What are the protein abundance variations of the proteomes studied?
- What are the partners of my protein of interest?
- Are there any signature proteins related to a particular biological process?

=> biomarkers identifications and quantifications

### **Biomarkers: applications to Duchenne dystrophy**



• **Death** of DMD patients usually occurs ~ 30's

### Serum: a "tricky" fluid for Mass Spectrometry

• Serum : Mixture of proteins with different ranges of proteins concentration



- Albumin : ~40 mg/ml (60% of serum proteome)
- C-reactive protein: ~1 µg/ml (40 000 times less than albumin)
- FGF-9 : ~400 pg/ml (100 000 000 times less than albumin)

Serum: Depletion of high abundance proteins

## Proteome Purify<sup>™</sup> 12

### R&D Systems

Human Serum Protein Immunodepletion Resin

 Antibody based column raised against the 12 most abundant proteins in serum

• Reduction of albumin by > 90%

Albumin-

Depletion of high abundance proteins gave us the highest number of identifications: selected for further analysis



### **Biomarkers: applications to Duchenne dystrophy**

Description	No. of peptides	Score	ANOVA ( <i>p</i> -value)	Fold change DMD/Healthy
Titin	23	1469.0	3.88E-06	37.4
Uromodulin	13	777.4	3.96E-03	5.5
Cubilin	10	576.8	2.55E-03	-2.3
Nuclear transport factor 2	5	356.9	1.05E-04	5.8
TNF-receptor superfamily member 16	4	308.7	4.07E-05	3.3
Myosin-1	3	265.3	8.66E-04	39.4
Fibulin-2	3	256.7	1.75E-03	2.9
β-galactosidase	6	253.7	1.23E-03	-2.4
Complement C1r subcomponent-like protein	5	235.8	3.47E-05	2.7
Aminopeptidase	3	213.7	2.71E-03	2.4

<u>From:</u> "Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy", J. Rouillon, A. Zocevic, T. Leger, C. Garcia, J-M. Camadro, B. Udd, B. Wong, L. Servais, T. Voit, F. Svinartchouk, 2014 Neuromuscular Disorders

### **Biomarqueurs: applications à la dystrophie de Duchenne**

No. accession	Description	Localization	Peptides	Score	ANOVA (P-value)	Fold change
MYG_HUMAN	Myoglobin	Cytoplasm	4	195	2.7e-03	234.8
MYOM2_HUMAN	MYOM2	Myofibril	10	390	9.8e-05	100.1
MYOM3_HUMAN	MYOM3	Myofibril	11	491	1.5e-05	49.7
TPIS_HUMAN	Triosephosphate isomerase	Cytoplasm	3	128	2.3e-03	48.4
AATC_HUMAN	Aspartate aminotransferase	Cytoplasm	3	75	4.7e-04	45.7
KCRM_HUMAN	CK-M	Cytoplasm	15	849	2.9e-05	39.8
MYH7_HUMAN	Myosin-7	Myofibril	11	520	2.2e-05	38.3
ENOB_HUMAN	β-en olase	Cytoplasm	4	178	7.4e-05	34.8
G6PI_HUMAN	Glucose-6-phosphate isomerase	Cytoplasm/Secreted	4	130	1.6e-03	29.5
CAH3_HUMAN	Carbonic anhydrase 3	Cytoplasm	5	182	8.6e-05	23.9
FLNC_HUMAN	Filamin-C	Myofibril	4	145	4.3e-04	19.4
ALAT1_HUMAN	Alanine aminotransferase 1	Cytoplasm	4	127	3.0e-05	15.6
ALDOA_HUMAN	Fructose-bisphosphate aldolase A	Cytoplasm	15	729	9.3e-05	14.2
KPYM_HUMAN	Pyruvate kinase PKM	Cytoplasm	16	845	1.1e-05	12.8
TITIN_HUMAN	Titin	Myofibril	14	495	1.9e-03	10.8
VINC_HUMAN	Vinculin	Cytoplasm/Membrane	2	74	7.2e-05	10.3
PYGM_HUMAN	Glycogen phosphorylase, muscle form	Cytoplasm	8	257	6.1e-04	9.9
LDHA_HUMAN	L-lactate dehydrogenase A chain	Cytoplasm	8	378	9.1e-04	9.5
HPT_HUMAN	Haptoglobin	Secreted	29	1867	1.5e-04	7.6
HBD_HUMAN	Haemoglobin subunit δ	Cytoplasm	3	100	5.1e-03	6.2
LDHB_HUMAN	L-lactate dehydrogenase B	Cytoplasm	10	598	2.4e-05	5.4
HBB_HUMAN	Haemoglobin subunit ß	Cytoplasm	7	552	8.0e-03	3.6
HBA_HUMAN	Haemoglobin subunit a	Cytoplasm	7	407	5.3e-03	3.4
TPM2_HUMAN	Tropomyosin ßchain	Myofibril	5	170	2.0e-02	2.6



Rouillon, J., Zocevic, A., Poupiot, J., Amor, F., Léger, T., Garcia, C., Camadro, J.M., Wong, B., Cosette, J., ML Coenen-Stass, A., McClorey, G., C Roberts, T., JA Wood, M., Servais, L., Voit, T., Richard, I., Svinartchouk, F. (2015). Serum proteomic profiling reveals specific MYOM3 fragments as biomarkers of Duchenne muscular dystrophy with applications for the follow-up of gene therapy treatment in a mouse model of muscular dystrophies. – Human Mol. Genetics

Jeremy Rouillon; Aleksandar Zocevic; **Thibaut Léger; Camille Garcia; Jean-Michel Camadro**; Bjarne Udd; Laurent Servais; Thomas Voit; Fedor Svinartchouk. (2014). *Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy*. <u>Neuromuscular disorders</u>.

## Protéomique ciblée de type PRM



# Why study PTMS?

- Cells can rapidly respond to stimuli and perturbations
- Important cellular mechanisms are tightly controlled
- Often, diseases (e.g. cancer) are due to aberrantly activated proteins
  - Protein expression is much too slow for quick adaption
  - PTMs are crucial regulator
  - MS-based proteomics allows to analyze complex networks of posttranslationally modified proteins



# PTMs in vivo

- Phosphorylation (Ser, Thr, Tyr; +80 Da)
  - Phosphorylation is one of the most important PTMs
  - A key event in signaling
  - Catalyzed by kinases/phosphatases
- Glycosylation (Asn, Ser, Thr)
  - marks proteins for degradation
  - s for degradation
- Glycation (Asn, Ser, Thr)
  - marks proteins for degradation
  - s for degradation
- Ubiquitination (Lys; +114 Da)
  - marks proteins for degradation
- Proteolytic cleavage
- Acetylation (N-termini and Lys +42 Da)
  - often combined with removal of protein initial Met

<u>Others</u>: oxidations, methylations, sumoylations, glutathionylations...

## PTMs characterization: techniques

### Techniques for detection and identification of PTM substrates

Method	In vitro or in vivo	Case studies	Advantages	Disadvantages
Radioactive isotope labeling	In vitro or in vivo	<sup>32</sup> P (pSer, pThr, pTyr) <sup>3</sup> H, or <sup>14</sup> C for <sup>Ac</sup> Ly <sub>5</sub> or <sup>M</sup> •K	Reagents accessible	Inconvenience/hazard low sensitivity
Western blotting	In vitro or in vivo	pTyr, <sup>Ac</sup> Lys or <sup>Me</sup> K	Good affinity	Moderate sensitivity
Peptide/protein array	In vitro	pSer/Thr/Tyr, <sup>Ac</sup> Lys or <sup>Me</sup> K	Rapid, global scale	Possibly non-specific, low sensitivity, requires verification
MS-proteomics	In vitro	pSer/Thr/Tyr, <sup>Ac</sup> R or <sup>M</sup> •K	Specific, global scale	Need enrichment methods

AcR, MeK, pSer, pThr, and pTyr, represent acetylated arginine, methyllysine, phosphorylated serine, threonine, and tyrosine residues, respectively.

## Workflow for PTMs characterization



Proteomics. 2009 Oct; 9(20): 4632-4641.

### **Quantitative proteomics and phosphorylations**





A32 Manuso	Phosphoprotein associated with glycosphingolipid-enriched micha	a transoucer activity memorane	;; response to stimulu	S	/63.10	646.62	45,9	4.81				
953 P20411	High affinity immunoglobulin epsilon receptor subunit gamma Cna	al transducer activity ell surface; membrane	to stimulus; transpor	t Pf11628	573.65	352.21	9.8	6.00				
963 Q64725	Tyrosine-protein kinase SYK OS=Rattus norvegicus GN=Syk Plna	al transducer activity cleus; organelle lumen	to stimulus; transpor	t Pf00017; Pf00069; Pf07714	4 835.28	323.20	71.5	8.15				
964	Sequence	# PSMs # Proteins	# Protein Groups	Protein Group Accessions	Modifications	MH+ [Da]	phosphoRS Site Probabilities	A4	IonScore A4	Exp Value A4	84 IonSco	ore B4
965	LLTLEDNELGSGNFGTVK	2 1		1 Q64725		1906.97726		High	107	1.50125E-10		
966	DESEQTVLIGSK	4 1		1 Q64725		1305.65435		High	84	2.49757E-08 H	igh	67
967	ELNGTYAISGGR	7 1		1 Q64725		1237.61919		High	55	2.38967E-05 H	igh	58
968	ADENYYK	3 1		1 Q64725		902,38894		High	46	0.000100972 -	igh	23
969	NVLLVTQHYAK	8 1		1 Q64725		1285.72683		High	44	0.000137239 -	igh	31
970	ISDFGLSK	6 1		1 Q64725		866.46208		High	42	0.000234007 -	igh	40
971	LIATTAHEK	7 1		1 Q64725		983.55124		High	37	0.000403124 +	igh	37
972	LRNYYYDVVN	4 1		1 Q64725		1318.64326		High	37	0.001486192 e	diu	24
973	YLEESNEVHR	4 1		1 Q64725		1293.62261		High	36	0.00176677 -	igh	27
974	MGCPPGCPR	4 1		1 Q64725	M1(Oxidation); C3(Carbamidon	1047,41679		High	35	0.000734469 -	igh	41
975	GSEVTAMLEK	2 1		1 Q64725		1064.52982		High	34	0.002136328		
976	GSEVTAMLEK	4 1		1 Q64725	M7(Oxidation)	1080.52370		High	34	0.002154235 e	diu	20
977	EVYLDRK	2 1		1 Q64725		922.49926		High	33	0.001493862		
978	ALRADENYYK	2 1		1 Q64725		1242.61182		High	30	0.007003353		
979	VLTVPCQK	5 1		1 Q64725	C6(Carbamidomethyl)	944.52278		Medium	25	0.020099256		
980	GSEVTAMLEKGER	1 1		1 Q64725	M7(Oxidation)	1422.68938		Medium	25	0.027162273		
981	LRNYYYDVVN	6 1		1 Q64725	Y4(Phospho)	1398.61077	Y(4): 93.9; Y(5): 5.7; Y(6): 0.4	Medium	24	0.023646873		
982	TGPFEDLKENLIR	2 1		1 Q64725		1531.81073		Medium	22	0.025122601		
983	GSEVTAMLEKGER	2 1		1 Q64725		1406.69446		Medium	20	0.067444564		
984	KPFNRPPGVQPK	1 1		1 Q64725		1364.77961		Medium	19	0.035807446		
985	LLTLEDNELGSGNFGTVKK	1 1		1 Q64725		2035.07124		Low	19	0.093821803		
986	WYAPECINYFK	1 1		1 Q64725	C6(Carbamidomethyl)	1490.67815		Low	17	0.171057347		
987	NYYYDVVN	2 1		1 Q64725		1049.45671		Low	16	0.121475657		
988	MGCPPGCPR	1 1		1 Q64725	C3(Carbamidomethyl); C7(Cart	1031.42131		Low	15	0.108098357		
989	MPWFHGNISR	1 1		1 Q64725	M1(Oxidation)	1260.59497		Low	13	0.348397318		
990	YLQQNR	1 1		1 Q64725		821.42674		Low	12	0.268819476		
991	NYLGGFALSVAHNR	1 1		1 Q64725	Y2(Phospho)	1598.76055	Y(2); 99.9; S(9); 0.1			Le	w	11
992 Q5U2U2	Crk-like protein OS=Rattus norvegicus GN=Crkl PE=1 SV=1 - [	protein binding m; cytosol; membrane	developmen	t Pf00017; Pf00018; Pf07653	3 234.55	96.32	33.8	6.74				
1005 P60868	40S ribosomal protein S20 OS=Rattus norvegicus GN=Rps20 Ftu	ural molecule activity ism; cytosol; ribosome	metabolic proces	s Pf00338	172.28	36.35	13.4	9.94				
## **Proteolytic cleavages as PTMs**

- Enzymes hydrolysant des liaisons entre acides aminés
- Classification des protéases : aspartate-, cystéine-, glutamate-, métallo-, sérine-, thréonine-, et les asparagine- protéases)
- Autres classifications



Acides aminés du site actif de la protéase

E. Jaspard (2013)

### **Biological functions of proteases**



#### **Various proteases**

#### □ Biological process regulations

- Protein turnover
- Misfolded proteins degradation
- Cell addressing
- Protein activation
- Deregulations associated to pathologic states

```
Model organism to study proteases
```

Vachova et al. 2007

#### Mca1p activation and apoptosis release



- Activée par de nombreuses molécules dont la molécule de quorum-sensing farnésol
- Pas d'informations sur la spécificité de clivage de ces substrats (coupures suspectées au niveau des résidus K et R )
- Un seul substrat caractérisé in vitro pour la métacaspase de S. cerevisiae (Gapdhp).

#### **Terminomics**



#### Recherche de la spécificité de clivage de Mca1p







#### Substrats potentiels de Mca1p et protéines de réponse aux stress

				- LAIP	ALA
Accession	Description	Experiment	Sequences	wi wi no no	* <b>*</b>
orf19.778	PIL1, composant de l'éisosome	Native	WGEDNEDDISDVTDK		MW (kD
orf19.7350	RCT1 Protéine induite par le fluconazole	Native	YDPKRSSNQGSSSSNDEQQDR		-170
Orf19.4309	GRP2, Methylglyoxal réductase	GluC	K.EKPNFTLSVINPVYVFGPQAFE		-130
Orf19.2340	CDC48; ATPase microsomale	GluC	R.FALGNSNPSALRE R.GQFSSFRFNE		-100 -70
orf19.2483	RIM1; protéine liant l'AND simple brin	GluC	K.VGSLVHVD		
orf19.2644	QCR2; Ubiquinol-cytochrome-c réductase	GluC	R.GLGNPLFYNE		-55
orf19.1435	TEF1; Facteur d'élongation	GluC	HALLAYTLGVK K.SGKVTGKTLLE		-40
orf19.6515	HSP90; Protéine chaperon essentielle	GluC	K.LVDAPAAIRTGQFGWSANME		-35
Orf19.6367	SSB1; Protéine de choc thermique (HSP70)	GluC	R.LIGRAFDDE		-25
orf19.4980	HSP70; Protéine chaperon de famille HSP70	GluC	K.LVSDFFNGKE K.RTLSSSAQTSIE		
orf19.1065	SSA2; Protéine chaperon de famille HSP70	GluC	K.RTLSSSAQTSIE R.LIGDAAKNQAAMNPANTVFD		-15
Orf19.5928	RPP2B; protéine ribosomale acide	GluC	R.LQALLKDLE		-10



#### 77 substrats potentiels de Mca1p (pour 62 protéines), dont 13 validés dans des conditions de sélection les plus drastiques

## **Proteomics workflows**



The strategy is dependent of the sample complexity

Search engine (Mascot, Sequest, Peaks, Maxquant, OMSSA, Prosight, Byonik)

## TOP DOWN proteomics for PTMs characterization



## Challenges in TOP-DOWN proteomics

Challenges	Innovations	
<ol> <li>Protein solubility</li> <li>Conventional surfactant (e.g. SDS) not compatible with MS</li> </ol>	Develop new top-down MS compatible surfactant	
<b>2. Proteome complexity</b> Intact protein chromatography under- developed	Develop novel multi-dimensional chromatography for intact protein separation	
<b>3. Proteome dynamic range</b> Difficulty in detecting low abundant proteins	Develop novel nanomaterials for enriching low abundant proteins	
<b>4. Protein MS data interpretation</b> Software for top-down proteomics underdeveloped	Develop user-friendly and versatile software interface	

# Analysis in intact protein mode: human brain glycogen phosphorylase



Crystal structure of human brain glycogen phosphorylase. Cécile Mathieu, Ines de la Sierra-Gallay, Romain Duval, Ximing Xu, Angélique Cocaign, Thibault Léger, Jean-Michel Camadro, Catherine Etchebest, Ahmed Haouz, Jean-Marie Dupret, Fernando Rodrigues-Lima. Under review.

## Analysis in intact protein mode



### Analysis in intact protein mode



# **Emerging MS** technologies









## Mass spectrometry imaging



- I Sacrifice and organ dissection
- III Matrix deposition
- V Reconstruction of intensity image
- II Cryosectioning and moving to ITO glass slideIV MALDI laser 2D scanning

## Mass spectrometry imaging



## Immunohistochemical validation





## SPIDERMASS

















https://leres.ehesp.fr/

# Thanks for your attention!!!

